Jin Shang, Ph.D., is the Senior Vice President of Global Regulatory Affairs at Adagene. She has more than 20 years of drug development experience in the biopharmaceutical industry.
Dr. Shang joined Adagene from AstraZeneca where she served as Director of Regulatory Affairs, Oncology. She provided global and US regulatory leadership for multiple oncology programs, including Koselugo®. Prior to AstraZeneca, Dr. Shang was Associate Director of Global Regulatory Strategy at Sun Pharma Advanced Research Company, where she led regulatory strategy development and implementation for multiple development programs for indications of oncology, ophthalmology, neurology, and dermatology. Prior to Sun Pharma, Dr. Shang was Director of Biology at Morphic Therapeutics, where she led the fibrosis biology team. Before Morphic, Dr. Shang worked at Merck Research Laboratories for twelve years on drug discovery and development in cardiometabolic diseases in a variety of positions of increasing responsibilities. She also worked at Lynx Therapeutics and Metabolex previously.
Dr. Shang began her career in the biopharmaceutical industry after obtaining her Ph.D. in Development Biology from Stanford University, and her bachelor’s degree in Cell Biology and Genetics from Peking University.